China Medical System Gains NMPA Clearance to Begin Clinical Trials for PNH Drug

SGX Filings

Jan 30

China Medical System Holdings Limited said on Jan, 30 2026 that China’s National Medical Products Administration has approved the company to start Phase I trials of its self-developed oral drug CMS-D017 in healthy volunteers.

CMS-D017 is a small-molecule inhibitor of complement factor B designed to block abnormal activation of the alternative complement pathway. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), with potential follow-on indications that include complement-mediated kidney diseases, age-related macular degeneration and myasthenia gravis.

The planned study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017.

If successfully developed and approved, CMS-D017 would expand the group’s nephrology portfolio alongside Velphoro and Oxemia, the latter of which is under regulatory review for renal anemia.

The company said it is preparing to launch the clinical programme promptly and will update investors on further progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126756280"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126756280\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126756280?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126756280","market":"sg","top_or_hot":-1,"title":"China Medical System Gains NMPA Clearance to Begin Clinical Trials for PNH Drug","media":"SGX Filings","content":"<p>China Medical System Holdings Limited said on Jan, 30 2026 that China’s National Medical Products Administration has approved the company to start Phase I trials of its self-developed oral drug CMS-D017 in healthy volunteers.</p>\n<p>CMS-D017 is a small-molecule inhibitor of complement factor B designed to block abnormal activation of the alternative complement pathway. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), with potential follow-on indications that include complement-mediated kidney diseases, age-related macular degeneration and myasthenia gravis.</p>\n<p>The planned study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017.</p>\n<p>If successfully developed and approved, CMS-D017 would expand the group’s nephrology portfolio alongside Velphoro and Oxemia, the latter of which is under regulatory review for renal anemia.</p>\n<p>The company said it is preparing to launch the clinical programme promptly and will update investors on further progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System Gains NMPA Clearance to Begin Clinical Trials for PNH Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System Gains NMPA Clearance to Begin Clinical Trials for PNH Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-01-30 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited said on Jan, 30 2026 that China’s National Medical Products Administration has approved the company to start Phase I trials of its self-developed oral drug CMS-D017 in healthy volunteers.</p>\n<p>CMS-D017 is a small-molecule inhibitor of complement factor B designed to block abnormal activation of the alternative complement pathway. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), with potential follow-on indications that include complement-mediated kidney diseases, age-related macular degeneration and myasthenia gravis.</p>\n<p>The planned study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017.</p>\n<p>If successfully developed and approved, CMS-D017 would expand the group’s nephrology portfolio alongside Velphoro and Oxemia, the latter of which is under regulatory review for renal anemia.</p>\n<p>The company said it is preparing to launch the clinical programme promptly and will update investors on further progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1126756280","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126756280","pubTimestamp":1769775021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited said on Jan, 30 2026 that China’s National Medical Products Administration has approved the company to start Phase I trials of its self-developed oral drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业获得NMPA批准开始PNH药物临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited said on Jan, 30 2026 that China’s National Medical Products Administration has approved the company to start Phase I trials of its self-developed oral drug CMS-D017 in healthy volunteers.\nCMS-D017 is a small-molecule inhibitor of complement factor B designed to block abnormal activation of the alternative complement pathway. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), with potential follow-on indications that include complement-mediated kidney diseases, age-related macular degeneration and myasthenia gravis.\nThe planned study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017.\nIf successfully developed and approved, CMS-D017 would expand the group’s nephrology portfolio alongside Velphoro and Oxemia, the latter of which is under regulatory review for renal anemia.\nThe company said it is preparing to launch the clinical programme promptly and will update investors on further progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}